Nurix Therapeutics, Inc.
NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for thā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$12.31
Price-1.68%
-$0.21
1Y
Price
Market Cap
$946.376m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-109.7%
EBITDA Margin-98.7%
Net Profit Margin-149.4%
Free Cash Flow MarginRevenue
$88.381m
+62.0%
1y CAGR+44.1%
3y CAGR+40.5%
5y CAGREarnings
-$207.320m
-7.1%
1y CAGR-7.1%
3y CAGR-18.8%
5y CAGREPS
-$2.61
+9.4%
1y CAGR+9.8%
3y CAGR-1.7%
5y CAGRBook Value
$447.603m
$591.555m
Assets$143.952m
Liabilities$51.931m
DebtDebt to Assets
8.8%
-0.2x
Debt to EBITDAFree Cash Flow
-$225.788m
-24.2%
1y CAGR-26.3%
3y CAGR-42.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company